Viome Life Sciences
PrivateLast Round
Series D
Sep 10, 2024
Total Funding Raised
$303.5M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Viome Life Sciences is a biotechnology and healthcare company that utilizes at-home clinical-grade tests and advanced RNA sequencing technology to analyze the human body and its microbiomes, providing personalized health insights and recommendations for chronic disease prevention and reversal.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, D2C Brands, Healthcare Analytics, Subscription Commerce
Business Model
B2C
Customer Profile
Hardware Sales, Hardware + Subscription
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Viome Life Sciences Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Viome Life Sciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Sep 10, 2024 | ||||
| Series C | Aug 18, 2023 | ||||
| Series C | Oct 18, 2022 | ||||
| Convertible Debt | Nov 10, 2021 | ||||
| Series B | Nov 1, 2019 | ||||
VC Round | Jul 6, 2018 |
Viome Life Sciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Ocgrow Ventures | Convertible Debt, Series C |
| Ezaki Glico Co., Ltd. | Convertible Debt, Series C |
| Khosla Ventures | Convertible Debt, Series D, Series C, Series A |
| Bold Capital Group | Convertible Debt, Series C |
| WRG Ventures | Series C, Series D |
| WestRiver Group | Convertible Debt, Series C |
| BOLD Capital Partners | Series B, Series A, Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 1, 2026
Added Ketch Kloud, Inc. (Technology/Data Privacy) as a customer.
- Jul 14, 2025
Developing an at-home RNA screening test for colon cancer with Scripps.
Viome Life Sciences Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Viome Life Sciences's valuation, stock price, and market status.